Growth Metrics

Armata Pharmaceuticals (ARMP) EBT Margin (2016 - 2020)

Quarterly results put EBT Margin at 15193.55% for Q2 2020, changed N/A from a year ago — trailing twelve months through Jun 2020 was 18229.91% (changed N/A YoY), and the annual figure for FY2017 was 6029.57%, down 358418.0%.

Armata Pharmaceuticals has reported EBT Margin over the past 6 years, most recently at 15193.55% for Q2 2020.

  • EBT Margin reached 15193.55% in Q2 2020 per ARMP's latest filing, down from 24270.0% in the prior quarter.
  • Across five years, EBT Margin topped out at 24270.0% in Q4 2017 and bottomed at 27725.0% in Q2 2017.
  • Median EBT Margin over the past 3 years was 4262.26% (2016), compared with a mean of 3881.12%.
  • The largest annual shift saw EBT Margin skyrocketed 1584233bps in 2016 before it crashed -2398617bps in 2017.
  • Over 3 years, EBT Margin stood at 13545.45% in 2016, then skyrocketed by 79bps to 24270.0% in 2017, then tumbled by -163bps to 15193.55% in 2020.
  • Business Quant data shows EBT Margin for ARMP at 15193.55% in Q2 2020, 24270.0% in Q4 2017, and 2050.0% in Q3 2017.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBT Margin (Qtr)
1 Quantum Biopharma 1,384,976.65 Bn 1,384,976.64 Bn - -
2 Alterity Therapeutics 777,208.84 Bn 777,208.81 Bn - -
3 Legend Biotech 2,801.00 Bn 2,800.10 Bn 242.10 Mn -6.43%
4 Nanobiotix 2,226.01 Bn 2,225.95 Bn - -
5 Akari Therapeutics 605.66 Bn 605.66 Bn - -
6 Vertex Pharmaceuticals 110.17 Bn 102.92 Bn 2.59 Bn 41.95%
7 Regeneron Pharmaceuticals 66.86 Bn 58.11 Bn 3.31 Bn 23.05%
8 Evaxion A 65.12 Bn 65.10 Bn - -
9 Alnylam Pharmaceuticals 39.94 Bn 36.94 Bn 959.66 Mn 18.99%
10 Armata Pharmaceuticals 301.92 Mn 297.17 Mn - -

Historic Data

Download Data 🔒
DateValue
Jun 30, 2020 -15,193.55%
Dec 31, 2017 24,270.00%
Sep 30, 2017 -2,050.00%
Jun 30, 2017 -27,725.00%
Mar 31, 2017 -11,586.21%
Dec 31, 2016 13,545.45%
Sep 30, 2016 -8,189.66%
Jun 30, 2016 -3,738.83%